The 'Dispatched' Podcast

Misleading claims about patient groups and the industry, combined with an irrational hyperventilation about a rational response to new global realities, have made for an interesting week. The price reduction mantra and whether it can be moderated?

A very busy week with mostly relief for patients accessing PBS-funded multiple sclerosis medicines, but what does it really mean, and what is the opportunity? Reports and their questionable citations. The most cynical use of language in our health system.

The MS medicines controversy continues. Why wouldn’t the minister just deal with it and make it go away? It may not be that easy. Why any resolution will probably deal with symptoms rather than the cause. The realities of ministerial offices and the challenges they face that are not visible to outsiders. Another 'phrase of the week' is dissected to reveal its true meaning.

A small player with no market share and no real prospect of gaining any agreed to an almost 50 per cent price reduction to secure reimbursement. Who would have thought the market leaders would respond negatively? Discussion about the change to nurse prescribing, which has been a feature of the PBS for more than 15 years, and concerns over vaccine hesitancy.

Congratulations to one of Australia's leading health journalists on a highly effective series of stories and commentaries that reveal the true extent of this country's challenge and the problems patients face in accessing medicines. A welcome hardening of the research-based industry's public position on the need for change, a very good report on a needed health technology, and another 'cheap' outcome for patients.

The emerging impact of China's use of international reference pricing might pose a significant risk to access to medicines in Australia. The critical importance of detail and getting the basics right when negotiating with the government - its ability to operate so effectively in the detail is how the government succeeds in these negotiations. Phrase of the week!

Why long-term thinking and planning are the key to success. What is the ten-year goal, and how does a new agreement progress that? Plan for policy and government engagement like it's a product launch. Also, is the problem with the HTA Review the process or the expectation? How a different starting point would have made this outcome positive.

Where did these industry agreements come from, and why? In the first episode of a two-part special, we discuss the genesis of the Australian government's agreements with the industry, based on personal experience, why they emerged as a solution to a decade-old challenge, and the problem they were aiming to solve. The opportunities, the risks, the vulnerabilities, and the importance of understanding how we arrived here.

Powerful patient stories stand in contrast to a decision-making framework that explicitly dehumanises their lived experience. The need for 'decency and compassion'. Week one of Senate Estimates, the challenge of saying one thing publicly and something else privately, and a Budget that revealed so much about what is coming.

There are enough measures and signals in this week's Budget to suggest medicines, vaccines and other technologies were discussed extensively in the process leading up to Tuesday's announcement. It might also help explain Health Minister Mark Butler's annoyance at one organisation's response. A Government response to a parliamentary inquiry triggered another odd response from stakeholder groups. 

In this week's episode, the focus is on the latest example of no progress on reform, the mindset and intransigence it reveals, the repeated pattern, and the early evidence that it would always end this way. Can it be an opportunity? Next week's Budget is upon us, and the discussion focuses on what to look for, that just because it is not in there, does not mean it is not in there, and why gaining any cut-through will be a real challenge.

In this special episode, the focus is on the official plan to force a 'consensus' on health technology assessment reforms through a process conducted in secrecy under the guise of ethics approval. The problem with running this policy process like a clinical trial is that we do not and will not know the identities of participants, how they were selected, their input, how it is used and weighted, or even the study protocol.

Tokenistic characterisations of patient engagement are no substitute for listening and empowering. The risk of government funding for organisations and how it can impact what they do, primarily because the government is just another vested interest. 

Another significant speech for the health portfolio that highlights the reform challenge and the importance of choices. A review announced in 2021 without an official response, and the reform of a major program announced with enabling legislation to be tabled next month. It's all about choices and priorities. Also, official recognition of discussions about managing a more assertive US on medicines pricing. What does it really mean?

An unhinged reaction to the new pharmacy prescribing initiative in New South Wales, why Australia needs to be humble in any health system comparison with the US, and given that the Government sets and umpires the rules for reimbursing innovative technologies, it can hardly complain when companies say no.

Australia’s health system is overly bureaucratic, opaque, and misaligned, with reforms like the HTA Review slowing access rather than improving it. Decision-making prioritises institutional processes over patients, who remain largely excluded despite bearing the consequences. The system is based on a transactional model, and without genuine patient-led change, core structural problems will continue.

In this week's episode, the discussion focuses on Health Minister Mark Butler's address at an event in Sydney and its invocation of history as the framework for pending negotiations over HTA reforms and PBS pricing. Also, strange comments by one senior official about evidence in healthcare decision-making send a clear signal about some of the thinking that might impact the next one to two years. 

A powerful patient story was overshadowed by a mindset that expects patients to simplify their needs and accept delays. Some proposed reforms risk entrenching these problems, while claims of having a 'world-class system' gaslight patients and seek to shut down scrutiny. This is about power. Institutions hold it, and patients are expected to adapt, meaning they must not relent in their push for change.

How Australia’s health system is failing patients by prioritising process and cost control over timely access to treatment, forcing more to rely on compassionate access programs. HTA processes are slow, often dehumanising, and used by the government as a delay tactic. Meaningful reform requires shifting away from process-driven decision-making toward real patient needs. The opportunity articulated this week by one leader is to pursue a more strategic approach to policy. The episode also highlights the growing role of pharmacy, which is increasingly based on trust and confidence, especially post-COVID, in contrast to struggling GPs.

In this episode, we examine funding uncertainty for genomic profiling through OMICO, structural tensions within the PBS and pharmaceutical supply chain, and broader concerns about how political and financial incentives shape health policy and budget decisions. The episode concludes with an uncomfortable discussion of recent public commentary on hostility against some communities (trigger warning).

Australia’s system for deciding whether new health technologies are funded is too focused on contested models and not enough on real people and their needs. The lack of human consideration leads to long delays, avoidable suffering, and sometimes deaths, in a process where patient voices are 'summarised' into oblivion while insiders talk around the problem instead of fixing it quickly, openly, and based on our shared values.

Reflect on  Susan Ley’s legacy as a former health minister, especially the 2015 PBS Access and Sustainability Package. She was treated rudely and unfairly, and that meaningful ecosystem reform has since stalled. Critique Senate Estimates, noting that departmental witnesses were evasive and overly defensive, with patients largely absent from the conversation. The discussion expands to reform and the lack of patient rights. Also note the troubling political rhetoric about medical information and regulation. Close by teasing upcoming upgrades to the BPD website.

Mark Butler’s four 'pillars' on medicines policy and the argument that Australia prioritises low prices over preventing shortages and ensuring access. Do we need smarter, targeted incentives to address shortages that often reflect global challenges? Is there a risk of 'process creep' that actually slows access? Aged-care reforms that unintentionally removed funding for dose administration aids and glucose monitoring.

The Government has announced an additional $25 billion for public hospitals over five years, representing close to two PBSs, while NDIS spending is still rising by $1 billion every few months. Can anyone seriously still argue that there is no new money available to invest in medicines? 

Not for the first time, some Australian politicians are in trouble over their use of very generous travel entitlements. We discuss why it matters for patients and why the claim that they are acting within the rules does not stack up.

A turbulent round of Senate Estimates, highlighted by a heartbreaking exchange about a mother with two children battling Crohn’s disease. Officials suggested that the family seek compassionate access from companies or seek treatment at a public hospital. We also canvass ‘MFN’ pricing risks, FOI controversies, ministerial travel blowouts and looming budget pressures that do not operate according to what might be a common understanding.

In this week’s Dispatched Podcast, we unpack the AI Health Summit and agree it revealed a gap between institutional caution and the real-world pace of its adoption. The practical reality of the proposed ban on genetic testing for life insurance, the self-limiting nature of Australia’s health reform processes, the status quo bias, and the absence of any genuine patient-centred purpose in current settings. We also discuss productivity, a critical roundtable, access inequities and the opportunity to broaden the discussion by not accepting the ‘framing’ of choices.

Reform efforts can struggle because they focus on health systems at their strongest point rather than their weakest. Framing is a pernicious tool used to justify delays and denials. We argue that the uptake of GLP-1 therapies in the US is delivering remarkable results, and that we need to apply the lessons from that experience in Australia, challenging institutional narratives and reframing the public debate to focus on public health benefits.

We discuss what could be a significant policy shift in PBS decision-making, with clinical judgement backed by what is a 'common sense' outcome. It could be a new precedent, but only if all stakeholders demand clarity on the criteria so that it can be applied more broadly. We also reflect on patient advocacy in New Zealand, where access has become a political issue and the focus of a significant discussion at this week's Valuing Life Summit in Wellington.

Has Senate Estimates devolved into an overly polite, time-sliced format that enables waffle, obfuscation, and endless questions taken on notice? Does this reflect weakened scrutiny? The responses provided revealed the truth of review processes, which aim to protect institutional power, blame outsiders for problems, and generally add complexity to existing problems. Few appear willing to say the quiet part out loud. Listen on Apple or Spotify.

We open by marking Yom Kippur and a frank discussion before pivoting to the US 'MFN' drug-pricing moves, what they could mean for Australia’s PBS, and why institutional rigidity in HTA persists and is worsening. Medical research funding rhetoric versus slow progress in PBS and health technology access, hospital funding and NDIS pressures, and the expansion of pharmacist prescribing, as well as the need for subsidised pharmacy services.

On the Dispatched Podcast this week, we reflect on the erosion of public confidence in health decision-making. Former Victorian Chief Health Officer Brett Sutton’s admission that some COVID-19 measures were not strictly evidence-based highlights the need for a Royal Commission, which would have compelled accountability and helped restore trust.The discussion then turns to MSAC’s rejection of newborn screening for Pompe disease. Health Minister Mark Butler must intervene, not least because he has previously pledged support to affected families.Looking abroad, Australia can look to New Zealand’s overhaul of Pharmac, particularly its decision to bring in external leadership and critics. It provides a model for cultural reform. In contrast, Australia’s system is mired in the same conversations among the same insiders.The podcast closes on the Trump administration’s proposed 'Most Favored Nation' pharmaceutical pricing policy and the new 100 per cent tariff. The Albanese Government, they predicted, would adopt a wait-and-see approach, shaped by a long history of industry warnings about lost access to medicines that rarely materialised.

In this week’s episode, the Medical Services Advisory Committee’s rejection of adding Pompe disease to newborn blood spot screening is condemned. The decision is contemptuous, inhumane, and riddled with fabricated justifications based on made-up terms like 'parental hypervigilance'. Families’ lived experience highlights the devastating cost of delayed diagnosis. The committee ignored evidence, misused language, and hid behind flawed economic models while dismissing patients. Health Minister Mark Butler and the Prime Minister can show moral leadership and finally honour their promises of 'never again'.

Patients should never accept a decision-making framework that requires them to sacrifice themselves for a mythical collective good, which is just the government getting the best deal for itself. More evidence of why we need to know what discussants present to HTA committees, and how they reflect personal opinions and ideologies. Financial results that confirm pharmacy's increasing role as a health destination.

The minister focused on NDIS reform at this week's National Press Club address, suggesting that it is taking up a lot of his time. Implementing the HTA Review will be one side of a two-sided coin. While it might frustrate some, it represents a unique opportunity to secure positive outcomes from an inevitable negotiation.

An update on the Government's travel policy! The opportunity of AI, our own journeys, and why it needs to be embraced and not feared, particularly in healthcare. Productivity and the impact of chronic conditions and another example of why it would be better to target support to those most in need.

Government travel policies make us laugh and laugh. Understanding reforms from the government's perspective is critical to understand how they will evolve over time, and an update that raises more questions than it answers.

A special episode focused on the AbbVie-commissioned survey, revealing firm support for increased investment in medicines and the true extent of patients paying the cost of their prescriptions. What does it mean and what is the opportunity?

Another order on pharmaceutical pricing, but what does it mean? What does the Government's productivity roundtable have in common with the HTA Review? Screening programs that aren't, and a co-payment reduction that puts the safety net further out of reach.

A sense of entitlement that needs to be questioned, Australia is on the list of nine countries to be targeted over pharmaceutical pricing, and the hopeless hypocrisy of allowing a group of disreputable regimes to have a say on this country's response to a pandemic, while fulminating about the US on the PBS.

The opportunity for Australia is to do less deflecting on healthcare affordability and engage in an honest discussion about the genuine challenges confronting many Australians. The debate does not just deflect on affordability.

The ongoing debate regarding the US, the Trump administration's potential tariffs on pharmaceuticals and the PBS is mainly characterised by falsehoods and errors. We discuss our incredible frustration over a debate that is almost entirely disconnected from facts, including the apparent belief that Australia has a vast array of advanced pharmaceutical manufacturing facilities. We also have praise for the Prime Minister following his statements at a media conference today.

We have more health commissioners, including for genomics, and we both hope for a more meaningful discussion on weight loss therapies, the opportunities, access barriers, and their system-changing impact. Telehealth is here to stay, particularly in specific therapeutic areas, while one state has introduced political donations reform that could have a broader impact.

The health department has released its incoming ministerial brief to the reappointed Mark Butler, revealing internal government discussions over the future funding of new PBS listings, and hinting at limiting the implementation of the HTA Review recommendations to a small number of technologies. It also contradicts the claim that new PBS listings take 466 days from TGA registration, suggesting that it actually takes almost 650 days.

In a country as wealthy as Australia, how is it fair or equitable that some can pay for new treatments, while most are forced to wait, while the government uses a laborious multi-year process to negotiate the best deal for itself? We are forced to live with a system that regularly treats human health like a failing business. Are we worth saving? We also live with a system whose underpinning framework is often considered inviolable and virtually unimpeachable.

Adding disability to health in an already full ministerial bandwidth and funding challenges. Trade policy and the PBS, and a presentation on the human consequences of our decision-making. Can a targeted diagnostic screening and the strangest patient case study?Times0:00 - 9.45: Adding disability to health in an already full ministerial bandwidth and funding challenges9.45 - 17:55: Trade policy, the PBS, and managing the risks and opportunities17:55 - 17:55: About a presentation on the human consequences of our decision-making37:50 - 44:52: Is it a public health measure or revenue raising?

A busy two weeks with an election and the addition of disability and the NDIS to the health portfolio. What does it mean? The credulous reflex response to comparisons between the US and Australian health systems. Why is denying access and out-of-pocket costs in Australia better than what happens in the US?